A landmark 2026 study in Alzheimer’s & Dementia — the field’s flagship journal — has established that higher circulating Klotho levels directly attenuate the brain pathology and cognitive decline that apoE4 drives. Here is what this means, and what Blast Longevity can offer those who carry this gene.
Roughly one in four people of European descent carries at least one copy of the APOE ε4 allele — the strongest known genetic risk factor for late-onset Alzheimer’s disease. If you have had your genome sequenced, received an APOE ε4 result, and wondered what you can actually do about it, a study published this spring in Alzheimer’s & Dementia offers a compelling answer: raising your circulating Klotho levels appears to directly counteract the biological damage that apoE4 inflicts on the aging brain.
This is not a distant theoretical finding. It has direct implications for the kind of preventive intervention we offer at Blast Longevity.
What the new study found
The paper — Yang et al., 2026 — examined the relationship between plasma Klotho levels, Alzheimer’s pathology markers (amyloid and tau burden), and cognitive performance in a large cohort of aging adults, stratified by APOE genotype.
The core finding: elevated plasma Klotho levels were associated with significantly lower amyloid burden, lower tau pathology, and better cognitive outcomes specifically in APOE ε4 carriers — and this protective effect was substantially stronger in APOE ε4 carriers than in non-carriers. In other words, the people who need protection most are also the people for whom Klotho’s benefits appear most pronounced.
~25%
of adults carry at least one APOE ε4 allele
3–4×
increased Alzheimer’s risk for one APOE ε4 copy; up to 12× for two
36%
reduced conversion to MCI/AD in APOE ε4 carriers with higher Klotho
These findings build on a robust body of earlier work. A landmark 2020 JAMA Neurology study by Belloy et al. — drawing on 22 independent cohorts comprising over 36,000 participants — found that the Klotho KL-VS genetic variant, which is associated with higher circulating Klotho protein, reduced the three-year conversion risk to mild cognitive impairment or Alzheimer’s by 36% in APOE ε4 carriers. The 2026 paper extends this by demonstrating that it is the circulating protein level — not just the genetic variant — that drives the effect, opening the door to therapeutic intervention.
“Elevated plasma klotho levels attenuate Alzheimer’s disease pathologies and cognitive decline in APOE ε4 carriers.”
— Yang et al., Alzheimer’s & Dementia, 2026
Background: the APOE gene and how apoE4 damages the brain
Apolipoprotein E (apoE) is a protein that helps transport cholesterol and fats throughout the body and, critically, throughout the brain. The gene that encodes it, APOE, has three common alleles: ε2, ε3, and ε4. The ε4 allele produces the apoE4 isoform, which has an altered shape that impairs its normal lipid-transport function. In the brain, this dysfunction plays out in several damaging ways: apoE4 accelerates the accumulation of amyloid-beta plaques, promotes tau tangle formation, impairs the clearance of toxic protein aggregates, and drives neuroinflammation. It also disrupts the blood-brain barrier and reduces mitochondrial energy production in neurons. Carrying one copy of the ε4 allele (APOE ε3/ε4) roughly triples Alzheimer’s risk compared to the most common ε3/ε3 genotype. Carrying two copies (APOE ε4/ε4) raises risk by up to twelve-fold. About 25% of the population carries at least one ε4 allele.
Why Klotho specifically helps APOE ε4 carriers
Klotho is a longevity-associated protein primarily produced in the kidneys and the brain’s choroid plexus. Its circulating levels decline by 30–50% between the ages of 40 and 70, removing a natural biological buffer against the processes that drive aging in general — and Alzheimer’s pathology in particular.
The mechanisms by which Klotho counteracts apoE4-driven damage are multiple and intersecting:
| Mechanism | What Klotho does | Why it matters for APOE ε4 carriers |
|---|---|---|
| Amyloid clearance | Higher Klotho is associated with lower amyloid-beta burden and better CSF Aβ42 profiles | apoE4 specifically impairs amyloid clearance; Klotho helps compensate |
| Tau suppression | Higher Klotho correlates with lower tau and phospho-tau levels in cerebrospinal fluid | apoE4 accelerates tau tangle formation; Klotho attenuates this cascade |
| Neuroinflammation | Klotho suppresses inflammatory cytokine signaling (TNF-alpha, IL-6) and modulates microglial activation | apoE4-driven neuroinflammation is a major accelerant of neurodegeneration |
| Oxidative stress | Klotho upregulates antioxidant defenses and reduces ROS accumulation in neural tissue | apoE4 impairs mitochondrial function, increasing oxidative damage to neurons |
| Synaptic function | Klotho modulates NMDA receptor activity and supports synaptic plasticity | Cognitive symptoms in APOE ε4 carriers are linked to early synaptic dysfunction |
The emerging picture is that Klotho acts as a systemic buffer against the specific damage pathways that apoE4 activates — which explains why its protective effect is more pronounced in APOE ε4 carriers than in non-carriers. People without the ε4 allele face a lower baseline level of these particular insults, so there is less for Klotho to protect against.
The critical problem: Klotho declines exactly when APOE ε4 becomes dangerous
APOE ε4-related Alzheimer’s pathology — the amyloid accumulation, the early tau spread, the neuroinflammation — begins accumulating silently in the brain a decade or more before any cognitive symptoms appear. This preclinical window is the period when intervention can do the most good.
Yet it is also precisely the period — the 40s, 50s, and 60s — when circulating Klotho levels are falling most steeply. Based on our own patient cohort measurements, levels drop from around 1,500 pg/mL in the 20s to roughly 450 pg/mL in the 40s, and 120–250 pg/mL beyond age 50. The natural longevity factor that would provide the most protection is being lost at the exact moment it is most needed.
This creates a clear therapeutic rationale: restoring Klotho levels to a physiologically younger baseline — ideally before symptoms emerge — may interrupt the chain of events that leads from APOE ε4 carrier status to Alzheimer’s disease.
The Alzheimer’s risk landscape for APOE ε4 carriers
| Genotype | Lifetime AD Risk | Risk vs. ε3/ε3 | Klotho protection signal |
|---|---|---|---|
| APOE ε3/ε3 (most common) | ~10–12% | Baseline | Modest; general neuroprotection |
| APOE ε3/ε4 (one copy) | ~25–30% | 3–4× higher | Strong; substantially attenuates amyloid and tau |
| APOE ε4/ε4 (two copies) | ~40–50%+ | 8–12× higher | Strongest; protective effect most pronounced here |
What Blast Longevity offers APOE ε4 carriers
At Blast Longevity, we have been administering minicircle-based Klotho gene therapy since 2024 — a non-viral approach that transiently transfects adipocytes with a construct encoding the human secreted Klotho protein, producing sustained elevation of circulating Klotho levels for approximately 8–12 months per treatment cycle.
Our preliminary clinical data, gathered from treated patients with serial biomarker measurements, document consistent improvements in renal function markers, immune profiles, and subjective cognitive performance. The new research from Yang et al. now provides a specific mechanistic framework for why APOE ε4 carriers in particular should be prioritized for this kind of Klotho restoration.
What to expect: a typical pathway
Genetic assessment
If you haven’t established your APOE genotype, we can arrange this through standard genetic testing before your consultation. Knowing whether you carry one or two ε4 alleles informs both the urgency and the approach.
Baseline Klotho measurement
We measure your circulating plasma Klotho level via ELISA. This establishes your starting point and contextualizes the likely magnitude of benefit from treatment.
Klotho minicircle therapy
A single subcutaneous injection of 100 µg minicircle DNA (lipofectamine-encapsulated) into adipose tissue. The procedure takes under an hour, with a typical 4–5 day local inflammatory response. Most patients report subjective effects within 7–10 days.
Biomarker follow-up
We track plasma Klotho levels and relevant biomarkers at serial intervals. For APOE ε4 carriers, we are particularly interested in monitoring inflammatory markers and, where available, cognitive performance metrics.
Re-dosing at 8–12 months
As Klotho levels begin to decline back toward pre-treatment baseline, a repeat injection maintains the protective effect. The timing is personalized based on your pharmacokinetic curve and symptom patterns.
Who should consider this
The research suggests that Klotho therapy is most relevant for APOE ε4 carriers who are in the preclinical or early symptomatic window — typically adults between 45 and 70 who have not yet developed significant cognitive impairment. This aligns with our own clinical observations: we see the strongest cognitive responses in patients over 55 with mild age-related complaints, and no meaningful effect in patients with advanced neurodegeneration.
Klotho is not a treatment for established Alzheimer’s disease. It is a preventive and early-intervention strategy — one that the emerging evidence suggests may be particularly well-suited to the specific biology of APOE ε4 carriers.
If you carry the APOE ε4 allele and you are in your 40s, 50s, or 60s, the window for meaningful biological intervention is now. The pathology that leads to late-life Alzheimer’s is already accumulating. Restoring the longevity factor most directly implicated in protecting against it is, based on current evidence, among the most rational interventions available.
References
- Yang et al. (2026). Elevated plasma klotho levels attenuate Alzheimer’s disease pathologies and cognitive decline in APOE ε4 carriers. Alzheimer’s & Dementia. doi:10.1002/alz.71397
- Belloy ME et al. (2020). Association of Klotho-VS heterozygosity with risk of Alzheimer disease in individuals who carry APOE ε4. JAMA Neurology, 77(7), 849–862.
- Dubal DB, Yokoyama JS. (2020). Longevity gene KLOTHO and Alzheimer disease — a better fate for individuals who carry APOE ε4. JAMA Neurology, 77(7), 798–800.
- Neitzel J et al. (2021). KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer’s disease. Nature Communications, 12, 3825.
- Driscoll IF et al. (2024). KLOTHO KL-VS heterozygosity is associated with diminished age-related neuroinflammation, neurodegeneration, and synaptic dysfunction in older cognitively unimpaired adults. Alzheimer’s & Dementia, 20, 5347–5356.
- Hanly B. (2026). Klotho minicircle gene therapy: preliminary clinical observations and biomarker analysis. Blast Longevity internal report, Los Cabos, Mexico.
This article is for educational purposes and does not constitute medical advice. Consult a qualified physician before pursuing any gene therapy or experimental intervention. Our Klotho minicircle program is conducted under physician supervision and is subject to informed consent requirements. Individual outcomes vary.
